Analysts press Biogen on lupus drug litifilimab ahead of pivotal readouts
Scrutiny of Biogen’s late-stage pipeline is intensifying ahead of several Phase 3 readouts that are pivotal to CEO Chris Viehbacher's turnaround efforts. Analysts lobbed numerous questions at Viehbacher and other Biogen execs about the trials ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.